Generic Name and Formulations:
Lithium carbonate 300mg; extended-release tabs.
Indications for LITHOBID:
Mania in bipolar disorder.
Swallow whole. Acute mania: 1800mg/day in 2–3 divided doses. Usual maintenance: 900–1200mg daily in 2–3 divided doses.
Increased risk of lithium toxicity in renal or cardiovascular disease, severely debilitated or dehydrated, sodium depletion, concomitant diuretics, ACE inhibitors, or ARBs: not recommended (if necessary, use low doses, monitor serum lithium levels daily). Brugada syndrome: avoid. Seizure disorders. Organic brain syndrome or other CNS impairment: monitor for neurologic toxicity. Maintain adequate fluid and salt intake esp. with fever, sweating, diarrhea, or infection. Monitor serum lithium levels frequently (toxic and therapeutic levels are close); draw blood for serum tests 8–12 hrs after previous dose. Monitor thyroid, renal function. Discontinue if diarrhea, vomiting, tremor, ataxia, drowsiness or weakness occur. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.
Lithium toxicity potentiated by diuretics, ACE inhibitors, ARBs, carbamazepine, indomethacin, piroxicam (possibly other NSAIDs, including COX-2 inhibitors), metronidazole, calcium channel blockers; monitor. Discontinue if signs of neurologic toxicity occur with neuroleptics (eg, haloperidol). Xanthines, acetazolamide, urea, alkalinizing agents may reduce serum lithium levels. Fluoxetine has variable effects on serum lithium levels. Prolongs effects of neuromuscular blockers. Hypothyroidism with chronic iodide administration. Serotonin syndrome with SSRIs.
Polyuria, polydipsia, drowsiness, tremor, hypothyroidism, extrapyramidal symptoms, nausea, renal toxicity, seizures, arrhythmias, hypotension, lethargy, metallic taste, dry mouth, blurred vision, pseudotumor cerebri (discontinue if occurs).
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally